FDA approves vepdegestrant, a PROTAC-based drug, marking a major shift in cancer therapy
The U.S. FDA's approval of vepdegestrant, the first PROTAC-based drug, for advanced breast cancer marks a significant advance in cancer therapy. PROTACs (proteolysis-targeting chimaeras) are designed to remove harmful proteins from cells, unlike conventional drugs that merely block them. This catalytic mechanism allows PROTACs to act multiple times and target "undruggable" proteins. Vepdegestrant specifically targets the oestrogen receptor, a driver of many breast cancers, offering new hope for patients with ESR1-mutated tumors. Despite challenges like molecule size and concentration-dependent activity, over 40 PROTAC candidates are in clinical trials for various diseases.
Key Points
- The U.S. FDA approved vepdegestrant, the first PROTAC-based drug, for ESR1-mutated, ER-positive, and HER2-negative advanced breast cancer.
- PROTACs (proteolysis-targeting chimaeras) remove specific harmful proteins from cells by recruiting E3 ligases for degradation, acting catalytically.
- This mechanism allows PROTACs to target proteins previously considered "undruggable" and potentially disrupt multiple protein roles.
- Vepdegestrant targets the oestrogen receptor, offering a new treatment for advanced breast cancer patients, including those resistant to hormone therapy.
- Despite challenges in absorption and concentration-dependent activity, over 40 PROTAC candidates are in clinical trials for various diseases.
Exam Facts
- U.S. FDA approved vepdegestrant on May 1.
- Vepdegestrant is the first PROTAC-based drug approved by FDA.
- PROTAC stands for proteolysis-targeting chimaera.
- Vepdegestrant developed by Arvinas and Pfizer.
- Phase 3 trial enrolled 624 patients.
- Early research on targeted protein degradation began in 2001 at Yale University and Caltech.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.